Tenoxicam-induced gastropathy in the rat: a comparison with piroxicam and diclofenac sodium, and the inhibitory effects of ranitidine and sucralfate.
The ulcer-inducing potential, indicated by the oral dose that induced gastric ulcers in 50% of rats, was higher for tenoxicam (10.2 mg/kg) than for diclofenac sodium (34 mg/kg, equivalent to 6.8 mg/kg tenoxicam) or piroxicam (6.2 mg/kg). The mean lesion scores, a measure of the intensity of ulceration, using 16 and 32 mg/kg tenoxicam given orally were 3.6 +/- 3.4 and 8.7 +/- 7.3, respectively, compared with 9.6 +/- 6.4 and 24.7 +/- 10.5, respectively, for similar oral doses of piroxicam; the differences were statistically significant (P less than 0.05 and P less than 0.001, respectively). The mean lesion score for 32 mg/kg tenoxicam was also significantly (P less than 0.05) less than that for 160 mg/kg diclofenac sodium: 8.7 +/- 7.3 compared with 14.8 +/- 8.1. Ranitidine (20 40 mg/kg) and 260-520 mg/kg sucralfate but not 4 mg/kg ranitidine strongly inhibited ulceration induced by 32 mg/kg tenoxicam.
al-Ghamdi
M S
MS
Department of Pharmacology, College of Medicine and Medical Sciences, King Faisal University, Dammam, Saudi Arabia.
Dissanayake
A S
AS
Cader
Z A
ZA
Jain
S
S
D000818:Animals; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000633:toxicity*; D004008:Diclofenac / Q000633:toxicity*; D004305:Dose-Response Relationship, Drug; D010894:Piroxicam / Q000031:analogs & derivatives* / Q000633:toxicity*; D011899:Ranitidine / Q000627:therapeutic use*; D051381:Rats; D011919:Rats, Inbred Strains; D013270:Stomach / Q000187:drug effects / Q000473:pathology*; D013276:Stomach Ulcer / Q000139:chemically induced* / Q000517:prevention & control; D013392:Sucralfate / Q000627:therapeutic use*
D000894:Anti-Inflammatory Agents, Non-Steroidal; D010894:Piroxicam; D004008:Diclofenac; D013392:Sucralfate; D011899:Ranitidine; C032801:tenoxicam